A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer

Inclusion Criteria

• •Have confirmed HR+, HER2+ early invasive breast cancer without evidence of disease recurrence or distant metastases
• •Have undergone definitive surgery of the primary breast tumor(s)
• •Have tumor tissue from breast (preferred) or lymph node
• •Have received a minimum of four cycles of chemotherapy in either the neoadjuvant or adjuvant setting per standard of care
• •Have completed approximately nine to 20 months of standard HER2-targeted therapy (neoadjuvant/adjuvant combined duration)
• •Have received one of the following eligible HER2-targeted adjuvant regimens AND be randomized within 12 weeks of completing the regimen:
• •* For participants treated with neoadjuvant therapy and HER2-targeted therapy: A minimum of 4 cycles of T-DM1 in the adjuvant setting. NOTE: Participants may have received up to approximately 6 cycles of adjuvant trastuzumab prior to initiation of T-DM1. Additionally, participants may have switched to trastuzumab-based therapy (monotherapy or in combination with other HER2-targeted therapies) after 4 cycles of T-DM1
• •* For participants who had definitive surgery prior to systemic therapy, a minimum of 4 cycles of adjuvant pertuzumab with trastuzumab.
• •Have high risk disease, defined by one of the following criteria:
• •* Those who received neoadjuvant chemotherapy along with HER2-targeted treatment must have:
• •* residual disease in at least one axillary lymph node, or
• •* a residual tumor ≥ 5 cm, or
• •* a residual tumor of any size that has direct extension to the chest wall and/or skin (ulceration or skin nodules).
• •* Those who had definitive surgery prior to systemic therapy and completed adjuvant chemotherapy along with HER2-targeted therapies (trastuzumab and pertuzumab) must have
• •* tumor involvement in ≥4 ipsilateral axillary lymph nodes, or
• •* tumor involvement in 1 to 3 ipsilateral axillary lymph node(s) and histological Grade 3, or
• •* primary invasive tumor size of ≥ 5 cm on pathological evaluation.
• •* Inflammatory breast cancer
• •Have other medical conditions including:
• •* Previous breast cancer (Exceptions: Ipsilateral ductal carcinoma in situ \[DCIS\] treated by locoregional therapy alone ≥5 years ago; contralateral DCIS treated by locoregional therapy at any time)
• •* Other cancer being treated and/or not in complete remission within the last 5 years (Exceptions: Appropriately treated non-melanomatous skin cancer or carcinoma in situ of cervix, bladder, or colon)
• •* Females who are pregnant or lactating
• •* History of venous thromboembolism
• •* Other serious medical conditions
• •Have previously received treatment with:
• •* Any cyclin-dependent kinase (CDK)4 and CDK6 inhibitor
• •* Prior adjuvant treatment with immunotherapy, tucatinib, neratinib, any investigational HER2 directed therapy, or T-DXd (DS8201) for treatment of breast cancer
• •* Endocrine therapy (ET) (i.e., tamoxifen, raloxifene or aromatase inhibitor) for breast cancer prevention (without diagnosis of breast cancer)
• •* Additional chemotherapy, anti-cancer ET, or HER2-targeted therapy beyond standard of care at study enrollment